Longer Control With Giredestrant and Everolimus in Endocrine-Resistant Breast Cancer

Why Does This Trial Matter?

HR+ / HER2- disease represents ~70% of all breast cancers. Endocrine treatments (such as aromatase inhibitors and fulvestrant) have long been central. Despite major advances with CDK4/6 inhibitors in recent years, important problems remain:

• Limited options after progression on CDK4/6 inhibitors.
• Increasing endocrine resistance through mechanisms such as ESR1 mutations.
• As survival after treatment lengthens, quality of life, oral options, and combination strategies become more important.

evERA is the **first positive** major Phase III trial fitting both “post-CDK4/6” and “oral SERD-containing combination.” It could therefore establish a new standard.

Trial Design and Patient Population

The EvEREA BC trial (NCT05306340) was designed as follows:

• Phase / Type: Phase III, randomized, open-label, multicenter.
• Population: ER-positive, HER2-negative locally advanced (unresectable) or metastatic breast adenocarcinoma; previous CDK4/6 inhibitor + endocrine therapy; ECOG performance status 0-1. 
• Randomization: Patients were assigned 1 : 1 to Giredestrant (30 mg/day) + Everolimus (10 mg/day) or investigator's choice endocrine therapy (e.g., exemestane, fulvestrant, tamoxifen) + Everolimus. 
• Stratification Factors: ESR1 mutation status, disease site (visceral vs other), prior fulvestrant. 
• Key Endpoints: Primary: Investigator-assessed PFS in the intention-to-treat population and ESR1-mutated subgroup. Secondary: OS, objective response rate (ORR), duration of response (DOR), clinical benefit rate (CBR), safety. 
• Number of Patients: Approximately 373 patients in total (Giredestrant n ~183, control n ~190). 
• Mutation Profile: Approximately 55% were ESR1 mutation-positive. 

Main Findings

The data presented at ESMO 2025 were: 

Additional notable findings:

• 6-month PFS rates in the ITT population: 57.4% with giredestrant, 39.6% in controls. 12-month rates were 34.1% and 18.1%, respectively. 
• Subgroups: Benefit also occurred in high-risk groups, such as those with visceral metastases or prior fulvestrant. 
• Although OS data remain immature, favorable trends were seen in ITT: HR 0.69 (95% CI: 0.47-1.00; p = 0.0473), and ESR1-mutated patients: HR 0.62 (95% CI: 0.38-1.02; p = 0.0566).

These results support a substantial, clinically meaningful PFS advantage over previous standards.

Safety Profile and Management Notes

Key safety findings included:

• Side effects matched the expected profile; no new safety signal was identified. 
• Common adverse events included stomatitis (~47%), diarrhea (~27%), and anemia (~24%). 
• Grade ≥ 3 adverse events were at a reasonable level; treatment discontinuation was uncommon. 
• Management must consider Everolimus-related complications such as stomatitis, hyperglycemia, and elevated lipids. No serious drug-specific toxicity has yet emerged prominently for the oral SERD Giredestrant.

The combination can therefore be viewed as balanced in efficacy and tolerability and a strong candidate for practical use.

Biological Background and Clinical Significance

The trial targets two important biological processes simultaneously:

1. Inhibition of Estrogen Receptor (ER) Signaling: Giredestrant is designed as an oral SERD (Selective Estrogen Receptor Degrader) and complete antagonist: it prevents estrogen binding, degrades the receptor, and inhibits ER-mediated cancer cell proliferation. 
2. mTOR Pathway Inhibition: Everolimus targets mTOR (mechanistic target of rapamycin), suppressing signaling networks supporting growth and survival. mTOR activation is common in endocrine-resistant cells.

The combination aims to overcome endocrine resistance from two directions: directly disrupting ER signaling and inhibiting downstream resistance-associated mTOR pathways.

The particularly large benefit in ESR1-mutated patients supports the clinical validity of a mutation-directed strategy. The trial demonstrates the value of resistance-focused endocrine combinations.

What Does This Mean for Clinical Practice?

Practical considerations include:

• HR+/HER2- advanced disease progressing after CDK4/6: Giredestrant + Everolimus is a strong candidate option.
• ESR1-mutated patients: The particularly striking PFS benefit means mutation status may inform planning.
• An oral regimen advantage: Both treatments are oral, offering practical benefits in convenience and quality of life.
• High-risk subgroups: Benefit also occurred with visceral metastases or prior fulvestrant, supporting broader applicability.
• Treatment management: Prevent Everolimus-specific toxicities such as stomatitis and hyperglycemia; monitor glucose, lipids, and oral care. Plan local protocols and patient education.
• Approval and access: Fully mature OS data are not yet available; regulatory and reimbursement processes may differ by country. Clinical decisions must consider this.

In conclusion, evERA provides, in HR+/HER2- advanced breast cancer, a strong step toward next-generation endocrine combination strategies implementation. It has the potential to move beyond current standards.

📚 References

1. Mayer E. L. et al. “Giredestrant + Everolimus in patients with ER+ HER2- advanced breast cancer previously treated with CDK4/6 inhibitor: primary results of the Phase III evERA BC trial.” ESMO Congress 2025 – Abstract LBA16. 
2. Roche Media Release. “Positive phase III results show Roche’s Giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer.” 22 September 2025. 
3. OncLive Coverage. Inman S. “Giredestrant/Everolimus Extends PFS for ER+, HER2- Advanced Breast Cancer.” 18 October 2025.